<DOC>
	<DOCNO>NCT00420030</DOCNO>
	<brief_summary>Outcome patient myocardial infarction complicate cardiogenic shock poor . Although early mechanical revascularization demonstrate superior conservative medical treatment , mortality range remain 45-60 % . Some medical registry show therapeutic benefit administration glycoprotein ( GP ) IIb/IIIa inhibitor PCI patient cardiogenic shock . However , randomize study support therapeutic strategy high risk patient . Hypothesis : GP IIb/IIIa inhibitor improve angiographic ( TIMI-flow ) , echocardiographic ( LV function ) clinical ( combine end-point ) outcomes patient myocardial infarction complicate cardiogenic shock . Study design : Open `` pseudorandomized '' multicenter , phase IV clinical trial . Anticipated finding : The investigator anticipate document well angiographic , echocardiographic clinical outcome upfront abciximab administration comparison standard periprocedural therapy patient undergo PCI cardiogenic shock . This would first randomize clinical trial could support therapeutic strategy .</brief_summary>
	<brief_title>Abciximab Patients Undergoing Percutaneous Coronary Intervention Cardiogenic Shock</brief_title>
	<detailed_description>Routine upfront abciximab versus standard peri-procedural therapy patient undergo percutaneous coronary intervention cardiogenic shock PRAGUE-7 Trial . Hypothesis : GP IIb/IIIa inhibitor improve angiographic ( TIMI-flow ) , echocardiographic ( LV function ) clinical ( combine end-point ) outcomes patient myocardial infarction complicate cardiogenic shock . Study design : Open `` pseudorandomized '' multicenter , phase IV clinical trial . The reason `` pseudorandomization '' ( i.e . randomization even odd date , PCI perform ) ethical : save time , critical clinical setting . It delay treatment , classical randomization cardiogenic shock may sometimes delay treatment 15 minute main reason randomize trial shock rarely able enroll patient . Groups : Group A - Upfront administration abciximab bolus follow 12-hours abciximab infusion + standard therapy Group B - Standard peri-procedural therapy possibility abciximab administration accord interventional cardiologist . Expected rate peri-procedural abciximab administration group 20 % patient . Allowed exclude concomitant medication see bellow table Group A Group B Before PCI Aspirin accord physician All treatment accord Clopidogrel accord physician physician Heparin bolus 70IU/kg body weigh Abciximab bolus 0,25 mg/kg body weigh During PCI Abciximab 12-hours infusion 0,125microgram/kg/min Abciximab accord Other treatment accord physician physician Excluded Thrombolysis , Eptifibatide , Tirofiban Thrombolysis , Eptifibatide , treatment Tirofiban Proposed sample size : 80 patient ( 40 patient group ) . This number patient permit complete study within &lt; 2 year . Because incidence cardiogenic shock study sample size support statistically . Objectives : Primary : Thirty-day clinical combine outcome : death / reinfarction / stroke / new renal failure . ( Death = death cause , reinfarction = recurrent ischemic symptom new increase CK-MB , stroke = new neurologic deficit last &gt; 24 hour , new renal failure = increase creatinine &gt; 300 micromol/l ) Secondary : 1 ) Combined end-point death / reinfarction / stroke / TIMI-flow &lt; 3 / EF &lt; 30 % day 30 . 2 ) Left ventricular EF assess echocardiography day 30 ( decease pt . EF assume 0 % ) 3 ) Rate major bleed complication 4 ) Myocardial blush score PCI 5 ) TIMI-flow PCI Statistical analysis : Thirty-day clinical outcome well categorical characteristic patient two group compare Fisher´s exact test . Group differences continuous factor compare Student´t-test Wilcoxon rank-sum test . Cardiac catheterization , PCI abciximab : Patients group undergo coronary angiography femoral access use 5F 6F sheath catheter . All patient receive standard antithrombotic anticoagulant treatment either transport directly catheterization laboratory . Patients randomize group A receive bolus abciximab give bolus dose 0,25mg per kg body weight immediately randomization ( either CCU , emergency dept . upon arrival cath-lab ) , follow infusion 0,125microgram/kg/min ( maximum 10microgram/min ) 12 hour . - PCI - perform immediately coronary angiography technically feasible . PCI perform infarct relate artery ( IRA ) . Intracoronary stent - implant possible . Type , length size stent choose accord decision invasive cardiologist - Abciximab - give patient randomize group A mention . Periprocedural abciximab bolus ( 0,25mg/kg ) follow 12-hours abciximab infusion ( 0,250 microgram/kg/min ) give selectively patient randomize group B accord decision invasive cardiologist - expect GPIIb/IIIa inhibitor ( abciximab ) give cca 10-20 % patient group ( current routine use GPIIb/IIIa blocker set ) . Angiographic data store CD . Independent invasive cardiologist blind clinical data blind randomization patient , assess TIMI flow IRA PCI ( grade 0-3 ) , myocardial blush score PCI area IRA ( grade 0-3 ) TIMI frame count PCI . Echocardiography : Complete echocardiographic examination perform 24hours , day 7 day 30 PCI . Vivid7 ultrasound system use . Data store digital form possible ( otherwise storage S-VHS use ) . Independent observer ass : - end-systolic enddiastolic diameter leave ventricle ( parasternal view ) - ejection fraction measure use Simson´s method - regional left ventricle function Ethical consideration : The approval local ethical committee require research protocol . Anticipated finding : We anticipate document good angiographic , echocardiographic clinical outcome upfront abciximab administration comparison standard periprocedural therapy patient undergo PCI cardiogenic shock . This would first randomize clinical trial could support therapeutic strategy .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Cardiogenic</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . Acute myocardial infarction ( ST elevation , ST depression bundle branch block ECG ) indication urgent coronary angiography 2 . Signs cardiogenic shock include incompletely develop shock ( least one follow must present ) : Hypotension ( BP &lt; 90mmHg ) HR &gt; 90/min Organ hypoperfusioncold wett sweat skin HR &gt; 90/min Need catecholamine support maintain BP &gt; 90/min Klip IIIII + systolic BP 120 mmHg 3 . Informed consent sign either patient his/her relative case diminish consciousness . 1 . Contraindications use abciximab , either : Hypersensitiveness Reopro component Active internal bleeding History stroke last 2 year Previous history ( last 2 month ) intracranial intraspinal surgical intervention Atriovenous malformation aneurysm Known haemorrhagic diathesis severe uncontrolled hypertension History thrombocytopenia Therapy oral anticoagulant ( warfarin ) 2 . Cardiogenic shock cause severe mitral regurgitation , rupture free leave ventricle wall interventricular septum . 3 . Prerandomization heparin dose &gt; 10 000 U last 6 hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>upfront abciximab</keyword>
	<keyword>PCI</keyword>
	<keyword>cardiogenic shock</keyword>
</DOC>